Literature DB >> 16103571

Angiotensin II, but not aldosterone and renin, correlates positively with increased concentrations of N-terminal pro-brain natriuretic peptide in patients with chronic heart failure.

O Gosling, M Martin, E Clarke, A Smith, E Coombes, M Dawes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16103571      PMCID： PMC1769096          DOI： 10.1136/hrt.2004.049809

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  5 in total

1.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.

Authors:  R W Troughton; C M Frampton; T G Yandle; E A Espiner; M G Nicholls; A M Richards
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

2.  Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

Authors:  Inder S Anand; Lloyd D Fisher; Yann-Tong Chiang; Roberto Latini; Serge Masson; Aldo P Maggioni; Robert D Glazer; Gianni Tognoni; Jay N Cohn
Journal:  Circulation       Date:  2003-03-11       Impact factor: 29.690

3.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.

Authors:  K Swedberg; P Eneroth; J Kjekshus; L Wilhelmsen
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

4.  Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length.

Authors:  S Wiese; T Breyer; A Dragu; R Wakili; T Burkard; S Schmidt-Schweda; E M Füchtbauer; U Dohrmann; F Beyersdorf; D Radicke; C J Holubarsch
Journal:  Circulation       Date:  2000-12-19       Impact factor: 29.690

5.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

Authors:  John J V McMurray; Jan Ostergren; Karl Swedberg; Christopher B Granger; Peter Held; Eric L Michelson; Bertil Olofsson; Salim Yusuf; Marc A Pfeffer
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.